Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples

In a recent study published in The Lancet, researchers investigated molecular properties of type 2 poliovirus (PV) isolates obtained from sewage samples (SS) to detect PV transmission in communities.

Study: Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Image Credit: Storm Media/Shutterstock
Study: Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Image Credit: Storm Media/Shutterstock

Background

PV transmission has affected all nations and has been designated an international public health emergency by the World Health Organization (WHO). The global PV outbreak risks could be aggravated in nations using inactivated polio vaccines, which confer robust protection against paralytic polio but have lesser efficacy than oral vaccines against PV shedding, probably enabling undetected PV circulation over a long period.

The present study's authors have previously conducted PV environmental surveillance in the United Kingdom (UK) from 2014 onwards. They found that vaccine-like PV isolates could be detected sporadically in wastewater (WW) samples, most probably imported from nations using oral polio vaccines for vaccinations and generating immune responses.

The authors had previously identified two, two, and eight vaccine-like PV isolates of type 1, 2, and 3, respectively, from 2017 to 2021, none of which were genetically related, and all comprised mutations, with no related viruses detected in subsequent WW samples, indicative of no local PV transmission.

About the study

In the present study, researchers extended their previous analysis by performing an environmental surveillance analysis for detecting PV type 2 isolates in sewage systems in London.

Ribonucleic acid (RNA) was extracted from SS and subjected to polymerase chain reaction (PCR) analysis using PV–enterovirus primers and sequenced by whole-genome sequencing. SS were tested using WHO-recommended techniques, including concentration, viral isolation in L20B mice and rhabdomyosarcoma cells, and molecular characterization. DDNS (direct detection by nanopore sequencing) and phylogenetic analyses were also performed.

In addition, a new nanopore sequencing protocol was used for direct PV detection in stool samples and rapid generation of whole genome PV sequences to improve understanding of their geographical transmission and history. In the modified protocol, type 2 PV isolate-targeted primers were used to improve viral detection sensitivity by decreasing the VP1 sequence background from the co-circulating C enteroviruses species obtained using the original detection protocol.

The sampling procedure was performed extensively to localize the region where PV transmission may occur. Beckton sewage treatment works were subcategorized into small sub-catchment regions. Sampling was also extended to larger London sewage treatment works plants beyond Beckton to investigate probable type 2 PV presence in wider geographical areas.

Results

Two PV type 2 vaccine-like isolates were identified in a sewage sample obtained from London Beckton sewage treatment work on 8 February 2022. In addition, three and six type 1 and type 3 PV vaccine-like isolates were identified in 52 SS obtained from London between 11 January and 4 July 2022, all of which comprised a few mutations without any genetic relationships except for the parent Sabin strain.

In total, 118 genetically-associated PV isolates genetically linked to the Sabin 2 vaccine strain (with six same mutations, including A481G and VP1-I143V site reversions) were identified in 21 (out of 52) sequential SS obtained in London between 8 February and 4 July 2022. The isolates acquired 11 more mutations between 8 February and 12 April 2022, at differing nt positions, increasing PV genetic diversity.

The isolates were recombinants with a species C enterovirus with a crossover at nucleotide (nt) position 5139. Out of 118 isolates, 20 met the criteria for vaccine-derived PV, with six to ten nt alterations in the VP1 capsid protein-encoding gene. The 20 isolates included vaccine-derived PV type 2 obtained from neighboring sewage areas with non-overlapped drainage populations, indicative of local PV transmission.

Only two samples (ENV-22-117 and ENV-22-027) comprised PV isolates with similar sequences. Genetically associated PV type 2 isolates were detected in increasing concentrations in the cell culture experiments performed on samples obtained from the London Beckton region from 12 April 2022 onwards.

Positive sampling locations identified indicated that PV was present mainly in a few regions within Beckton and several boroughs located in the east and north of London. When using type 2 PV isolate-specific primers in the second nested PCR test, increased sensitivity was observed. Type 2 PV isolates could be detected from stool samples reported as negative by viral isolation experiments.

Conclusions

Overall, the study findings showed that environmental surveillance enabled the detection of PV importation (and circulation) in London in the early stages, allowing swift public health responses, including increased surveillance and an inactivated polio vaccine campaign in one-year to nine-year-old children. The viruses appeared to undergo evolution in several directions originating from a common source, with multiple London sewage PV type 2 isolates sharing only one or similar VP1 nt alterations from the Sabin 2 strain, indicating that genetic associations between the isolates were not only based on VP1 sequences.

Therefore, it may be critical to refine vaccine-derived viral organism definitions to ensure the rapid and early detection of PC transmission events, especially in nations free of polio for several years.

Journal reference:
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Pooja Toshniwal Paharia is an oral and maxillofacial physician and radiologist based in Pune, India. Her academic background is in Oral Medicine and Radiology. She has extensive experience in research and evidence-based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2022, October 17). Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples. News-Medical. Retrieved on October 09, 2024 from https://www.news-medical.net/news/20221017/Scientists-use-enhanced-environmental-surveillance-for-poliovirus-type-2-detection-in-London-sewage-samples.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples". News-Medical. 09 October 2024. <https://www.news-medical.net/news/20221017/Scientists-use-enhanced-environmental-surveillance-for-poliovirus-type-2-detection-in-London-sewage-samples.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples". News-Medical. https://www.news-medical.net/news/20221017/Scientists-use-enhanced-environmental-surveillance-for-poliovirus-type-2-detection-in-London-sewage-samples.aspx. (accessed October 09, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2022. Scientists use enhanced environmental surveillance for poliovirus type 2 detection in London sewage samples. News-Medical, viewed 09 October 2024, https://www.news-medical.net/news/20221017/Scientists-use-enhanced-environmental-surveillance-for-poliovirus-type-2-detection-in-London-sewage-samples.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Houston Methodist researchers join national consortium to develop herpesvirus vaccine